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Jo-Anne Riley,a Tom Brown,a Nittaya Gale,b Julie Hernimana and G. John Langley*a
Hybridisation assays, which are commonly used to analyse oligonucleotides such as siRNAs and miRNAs,
often employ detection probes with ﬂuorescent tags. The signal emitted by a ﬂuorescent tag covers a
broad range of wavelengths and this limits the multiplexing potential due to overlapping signals. A novel
method of indirect oligonucleotide analysis has been developed which combines a hybridisation assay
with cleavable small molecule mass tags using HPLC-ESI MS detection. A self-reporting detection probe
has been designed which incorporates a DNA/RNA chimeric oligonucleotide sequence in the reporter
region, which generates small nucleotide products upon RNase cleavage of the ribose-phosphate
backbone. These small nucleotides can then serve as mass tags for the indirect detection of
oligonucleotide analytes. The narrow mass range covered by a small molecule mass tag combined with
the wide range of possible mass tags provides a high degree of multiplexing potential. This approach has
been demonstrated for the analysis of a synthetic miRNA.Introduction
Small interfering RNAs (siRNAs)1 and microRNAs (miRNAs)2 are
short (20 nt) oligonucleotides which are involved in genetic
regulation. Through recently discovered naturally occurring
mechanisms, these oligonucleotides can regulate protein
synthesis in vivo by base pairing to complementary messenger
RNA (mRNA) to prevent translation. This type of regulation has
been shown to be important in many normal cellular processes3
and has also been linked to a wide variety of diseases.4 The
understanding of these regulatory mechanisms has provided
the potential to use oligonucleotides as therapeutic agents to
treat many diseases. Consequently, novel methods of oligonu-
cleotide analysis are required to support the drug discovery and
development process.
Standard methods of RNA analysis now rely on hybridisation
assays with uorescence detection. In a hybridisation assay an
oligonucleotide analyte is captured onto a solid support using
an immobilised complementary probe. Sandwich hybridisation
assays use a detection probe designed with a region comple-
mentary to part of the target analyte and a labelled reporter
region5,6 (Fig. 1). Alternatively, reverse transcription of an RNA
analyte can be performed in the presence of uorescently
labelled dNTPs to produce uorescently labelled cDNA, which is
then used as a surrogate for the RNA.on, Southampton, SO17 1BJ, UK. E-mail:
, Southampton, SO17 1BJ, UK. E-mail:
91; Tel: +44 (0)23 8059 6778A uorescent label generates a broad signal covering a wide
wavelength range. This limits the use of uorescent labels in a
multiplexed system due to overlapping signals. Two colour
systems are oen employed where two uorescent labels are
used for RNA from two diﬀerent biological samples, e.g. two
diﬀerent cell types or diseased and non-diseased tissue.
Samples can then be mixed and analysed simultaneously for a
direct comparison.Fig. 1 Schematic of the sandwich hybridisation assay with ﬂuores-
cence detection.
This journal is © The Royal Society of Chemistry 2014
Fig. 2 Structures of small molecule mass tags designed to be
produced upon RNase A digestion of (a) detection probe 1 and (b)
detection probe 2. Upper case ¼ DNA, lower case ¼ RNA, uBr ¼
5-bromouridine, p ¼ 30 0 phosphate.
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View Article OnlineAn alternative to using uorescent tags is the use of cleavable
small molecule mass tags, which can be employed for the
indirect analysis of large biomolecules with detection by mass
spectrometry. Mass tags have been used for oligonucleotide
analysis where a small molecule label was conjugated to an
oligonucleotide probe via a synthetic photocleavable linker
which was cleaved during the matrix-assisted desorption/ioni-
sation (MALDI) process7–10 or a synthetic linker cleaved during
the electrospray ionisation (ESI) process.11
Previous work has shown that the ribose-phosphate back-
bone of RNA can be used as a built-in enzyme cleavable linker,
which upon cleavage of custom designed oligonucleotides with
a specic ribonuclease can produce mono- di- or trinucleotide
digestion products. These small molecules could themselves be
used as mass tags with HPLC-ESI MS or MALDI-TOF MS analy-
sis.12 Here, this approach has been combined with a hybrid-
isation assay, where the detection probe has been designed to
include a target specic region at one end and a DNA/RNA
chimeric reporter region at the other end. This reporter region is
designed to produce bromine labelled small molecule mass tags
upon RNase digestion. Use of these self-reporting probes has
been demonstrated for the indirect analysis of miRNA as an
alternative to uorescent labels for oligonucleotide analysis,
giving a greater potential for multiplexing.
miRNA-155 was chosen as target analyte for this proof of
concept hybridisation assay due to the wide range of processes
it is reported to aﬀect, including the immune system13 and
autoimmune diseases14 including rheumatoid arthritis,15
lupus,16 and multiple sclerosis.17Fig. 3 Schematic of the sandwich hybridisation assay using HPLC-ESI
MS for the detection of small molecule mass tags enzymatically
cleaved from a self-reporting detection probe for the indirect analysis
of miRNA-155.Results
A biotinylated capture probe and a self-reporting detection
probe were designed to target the miRNA-155 sequence
(Table 1). The reporter region of the detection probe was
designed to be cleaved by RNase A to release the bromine
labelled dinucleotide mass tag AuBrp into solution (Fig. 2(a)).
RNase A is an endoribonuclease which cleaves the phosphate
group at the 30 side of cytidine and uridine bases to produce
30 phosphate and 50-OH oligonucleotides and also cleaves at the
30 side of 5-bromouridine.
A sandwich hybridisation assay was performed with bio-
tinylated capture probe, detection probe 1 and miRNA-155
(Fig. 3). A control assay which omitted miRNA-155 was alsoTable 1 Oligonucleotide sequencesa
ID Sequence (50/ 30)
Capture probe CGATTA + G + C + AT
Detection probe 1 TTTTTTcAuBrAuBrAuB
Detection probe 2 TTTTTTcTuBrTuBrTuB
miRNA-155 uuaaugcuaaucgugaua
RNA-c uuaaugcuaaucgugaua
RNA-a uuaaugcuaaucgugaua
RNA-u uuaaugcuaaucgugaua
RNA-scrambled aggugcaugucgaauuag
a Upper case ¼ DNA, lower case ¼ RNA, uBr ¼ 5-bromouridine, + ¼ LNA,
This journal is © The Royal Society of Chemistry 2014performed. Following the hybridisation, capture, washing and
enzyme digestion steps, HPLC-ESI MS analysis of the solution of
the assay containing miRNA-155 showed that AuBrp wasMW(av)
TAATTT-biotin 5537.9
rTTTTTACC + C + C + TATCA 8790.1
rTTTTTACC + C + G + TATCA 8789.1
ggggu 7389.4
cgggu 7349.4
agggu 7373.4
ugggu 7350.4
uauug 7389.4
underline ¼ site of mutation.
Analyst, 2014, 139, 1088–1092 | 1089
Fig. 4 EICCs of m/z 713.5–718.6 ([AuBrp  H]) for the hybridisation
assay containing capture probe, detection probe 1 and no analyte
(grey) or RNA analyte miRNA-155 (pink). Inset shows negative ion ESI
mass spectrum of [AuBrp  H].
Fig. 6 EICCs ofm/z (a) 704.5–709.6 ([TuBrpH]) and (b) 713.5–718.6
([AuBrp  H]) for the hybridisation assay containing capture probe,
detection probe 1, miRNA-155, detection probe 2 and RNA-c.
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View Article Onlineobserved. The singly deprotonated species was seen with the
distinctive bromine isotope pattern, giving a peak in the
extracted ion current chromatogram (EICC) at tR 6.5 min. For
the control assay, no evidence of AuBrp was observed by UV or
MS, i.e. the mass tag was only observed when the analyte was
present (Fig. 4).
The specicity of the hybridisation assay was evaluated by
using RNA analytes with the sequence of miRNA-155 but with
single base substitution mutations at position 19 (RNAc, RNAa
and RNAu, Table 1) in place of miRNA-155. HPLC ESI MS
analysis following these assays showed that for the assays
containing RNA-c or RNAu no evidence of the mass tag was
observed, however for the assay containing RNA-a AuBrp was
observed. This highlights a limitation of hybridisation assays
for oligonucleotide analysis (Fig. 5). The UV and the MS peak
areas relating to the mass tag for the assay containing RNA-a
were 18% and 28%, respectively, compared to the assay con-
taining the target analyte.
To test the potential for multiplexing, a detection probe was
designed to target RNAc with a reporter region designed toFig. 5 EICCs of m/z 713.5–718.6 ([AuBrp  H]) for the hybridisation
assays containing capture probe, detection probe 1 and RNA analyte;
miRNA-155 (pink), RNA-c (light blue), RNA-a (green), RNA-u (blue) and
RNA-scrambled (orange).
1090 | Analyst, 2014, 139, 1088–1092produce the mass tag TuBrp (Fig. 2(b) and Table 1). An assay was
performed with biotinylated capture probe, detection probe 1,
miRNA-155, detection probe 2 and RNAc. Following the
hybridisation assay, capture, washing and enzyme digestion
steps, HPLC-ESI MS analysis of the solution showed both mass
tags AuBrp and Tu
Br
p were observed as the singly deprotonated
species (Fig. 6).Discussion
Results of the assays presented above demonstrate that HPLC-
ESI MS can be used for the indirect analysis of miRNA via
cleavable small molecule mass tags. Integration of the custom
designed sequence at the reporting end of the detection probe
allows the production of cleavable small molecule mass tags
without the need for custom design or synthesis of a cleavable
linker, which is required by existing mass tag technologies.
Locked nucleic acids (LNAs)18,19 were incorporated into the
design of the capture and detection probes as they have been
shown to improve base pair mismatch discrimination.20
Washing steps were also performed prior to analysis to ensure
the assay is specic for the target analyte. However, oligonu-
cleotides with sequences similar to the target analyte, e.g. with
single base substitution mutations, can hybridise to probes
designed for the analyte, although the stability of the mis-
matched duplex, i.e. melting temperature (Tm), will be lower. If
the mismatched sequence remains bound, it will produce a
signal for the mass tag and if present in an assay which also
contains the target sequence it will contribute to the signal of
the analyte. Inability to discriminate between similar sequences
is a limitation of hybridisation assays, however only one of the
mismatched analytes tested gave a signal for the mass tag,
whereas for the other mismatched analytes, no evidence of the
mass tag was observed (Fig. 5).
A signicant advantage of the approach presented here over
assays which use uorescence detection is the potential for
multiplexing. Signals produced by uorophores are broad,
typically covering around 100 nm in a wavelength window of
approximately 600 nm. In contrast, ion signals from bromineThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinelabelled small molecule mass tags cover in the region of 6 Da,
taking into account all isotopic contributions, in amass window
of approximately 1000 Da. This allows many mass tags to be
simultaneously analysed without overlapping signals. By using
nucleotide digestion products as small molecule mass tags, the
identity of the bases, and therefore the masses of the digestion
products, can be changed to give a range of possible mass tags.
This range of mass tags could be further extended by the use of
chlorine or multiple chlorine and/or bromine atoms as labels or
synthesis of bases containing custom isotope patterns. Intro-
ducing additional functional groups would also further extend
the multiplexing possibilities.Experimental
Materials and reagents
Trizma base, NaCl, acetylated bovine serum albumin (BSA),
sodium dodecyl sulfate (SDS), ammonium acetate and RNase A
were biological grade and were obtained from Sigma (Poole, UK)
and used without further purication. Magnetic beads used
were Dynabeads® MyOne Streptavidin C1 (Life Technologies).
All water used was obtained from an Elga system at 15 MU and
was autoclaved prior to use.Oligonucleotide synthesis and purication
Oligonucleotide synthesis was performed on an Applied Bio-
systems 394 automated DNA/RNA synthesiser. The phosphor-
amidite monomers used for DNA/RNA/LNA chimera synthesis
were dmf-dG-CE, Bz-dA-CE, Bz-dC-CE, dT-CE, 5-Br-rU-CE and
Ac-rC and were purchased from Link Technologies Ltd
(Lanarkshire, UK) and Applied Biosystems Ltd (Paisley, UK).
The LNA amidites used were LNA™-A(Bz), LNA™-mC(Bz),
LNA™-G(dmf) and LNA™-T purchased from Exiqon (Vedbæk,
Denmark). All oligonucleotides were synthesised on standard
1.0 mmol DNA phosphoramidite cycle, except where stated, with
the following steps; acid catalysed detritylation, coupling,
capping and iodine oxidation. Directly before use, b-cyanoethyl
phosphoramidite RNA and DNA monomers were dissolved in
anhydrous acetonitrile, to a 0.1 M concentration. The LNA
monomers were also dissolved in acetonitrile except LNA™-
mC(Bz) which was dissolved in anhydrous THF–acetonitrile
(4 : 6, v/v) and le over 3 A˚ activatedmolecular sieves for 4 hours
before use. Coupling time for the standard DNA monomers was
40 seconds and for the RNA and LNA monomers was 480
seconds. For the rst monomer aer the biotin TEG resin,
coupling time was extend to 120 seconds using 5-benzylthio-1H-
tetrazole (BTT) as the coupling reagent. Oxidation time for the
RNAs/LNAs was extended from 15 seconds to 40 seconds.
Cleavage from the solid support in conjunction with exocyclic
amino group deprotection was completed by exposing the
solution to a mixture of aqueous ammonia and ethanol (3 : 1,
v/v) for 12 hours at room temperature.
Purication of oligonucleotides was achieved by reversed-
phase HPLC using a Gilson system with an 805 manometric
module, 811C dynamic mixer, 306 pump and a 118 UV/vis
detector. A Phenomenex C8 column (10 mm, 10 mm  250 mm)This journal is © The Royal Society of Chemistry 2014was used for separation. The following protocols were used: run
time 20 min, ow rate 4 mLmin1, binary gradient: time in min
(% buﬀer B); 0 (0); 3 (0); 3.5 (5); 15 (45); 16 (100); 17 (100); 17.5
(0); 20 (0). Buﬀer A: 0.1 M triethylammonium acetate (TEAA) in
water, pH 7.0, buﬀer B: 0.1 M TEAA in water–acetonitrile (1 : 1),
pH 7.0. Elution of oligonucleotides was monitored by UV
absorption. Oligonucleotides were then desalted using NAP 25
and NAP 10 Sephadex columns (G 25, GE-Healthcare), aliquoted
into eppendorf tubes and stored at 20 C.
Buﬀer preparation
Binding buﬀer was prepared as 10 mM tris and 1 M NaCl in
water, adjusted to pH 7.2 with HCl. Wash buﬀer was prepared as
10 mM tris and 0.1% SDS in water. Ammonium acetate buﬀer
was prepared as 220 mM ammonium acetate in water.21 All
buﬀers were ltered and degassed prior to use.
Hybridisation assays
Each hybridisation assay with individual analytes was under-
taken using the following oligonucleotides: capture probe
(150 pmol), miRNA analyte (150 pmol) and detection probe
(200 pmol) in binding buﬀer (250 mL). For the control assay the
analyte was omitted. For the assay using two analytes the
following oligonucleotides were used: capture probe (300 pmol),
miRNA-155 (150 pmol), RNA-c (150 pmol), detection probe 1
(200 pmol) and detection probe 2 (200 pmol) and the amount of
beads and volumes of buﬀers used were doubled. Samples were
heated to 90 C for 15 minutes and then cooled to room
temperature over 1 h for annealing to take place. Streptavidin
coated magnetic beads (30 mL, 300 mg) were washed with
binding buﬀer (3 500 mL) and then to the beads was added the
hybridised oligonucleotide solution along with BSA (0.1%). The
solution was vortexed and then incubated at room temperature
for 30 min for immobilisation. The beads were then isolated
using a magnet, washed with binding buﬀer (2  500 mL), wash
buﬀer (2  500 mL) and water (2  500 mL) and resuspended in
binding buﬀer (250 mL). The solution was then heated to 56 C
for 10minutes, a temperature which was determined bymelting
temperature analyses. The solution was then washed with
binding buﬀer heated to 56 C, (2  500 mL), wash buﬀer (2 
500 mL) and water (2 500 mL) and re-suspended in ammonium
acetate buﬀer (20 mL). The assay was then heated to 37 C and
RNase A was added (10 mL, 0.1 Kunitz units22 per mg detection
probe, in ammonium acetate buﬀer) and the solution was
incubated at 37 C for 10 minutes. The beads were then isolated
and 5 mL supernatant was diluted in 15 mL water and analysed
using HPLC-ESI MS.
HPLC-ESI MS analysis
HPLC separation was performed using a Dionex UltiMate 3000
liquid chromatography system with a quaternary solvent
delivery system, UV/visible detector, heated column compart-
ment and chilled autosampler (Dionex, Hemel Hempstead, UK).
An Acquity UPLC BEH C18 column (1.7 mm, 1 mm  100 mm,
Waters, Milford, MA, USA) was used for separation. The column
temperature was set to 40 C and UV absorbance was measuredAnalyst, 2014, 139, 1088–1092 | 1091
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View Article Onlineat 290 nm. A binary gradient solvent system was used with
mobile phase A consisting of 10 mM TEAA and 100 mM hexa-
uoroisopropanol (HFIP) in water and mobile phase B con-
sisting of 20mMTEAA in acetonitrile. Mobile phase B was at 1%
for 1 minute, then increased to 20% over 7 minutes, then
increased to 40% over 2 minutes and then returned to 1% until
13 minutes. A ow rate of 100 mL min1 and a 2 mL injection
volume were used. Negative ion ESI data were acquired using a
MicrOTOF (Bruker, Bremen, Germany) mass spectrometer
over the m/z range 250–3500. Data were analysed using Data
Analysis™ soware v4.0.
Conclusions
Self-reporting probes have been used in a sandwich hybridi-
sation assay for the indirect analysis of miRNA with HPLC ESI
MS detection. The probes which have an analyte complemen-
tary region at one end and a DNA/RNA chimeric reporter region
designed to produce small molecule mass tags upon RNase A
cleavage at the other end. Use of the ribose-phosphate group of
the RNA molecule as an enzyme cleavable linker eliminates the
need for design and synthesis of a cleavable linker and this
approach provides a much higher degree of multiplexing
potential than commonly used uorescent labels.
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